AAA
ATXS

Affinity Asset Advisors’s Astria Therapeutics ATXS Stock Holding History

Affinity Asset Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300,000
Closed -$2.18M – 97
2025
Q3 		$2.18M Hold
300,000
– – 0.19% 73
2025
Q2 		$1.61M Buy
+300,000
New +$1.45M 0.22% 62
2024
Q4 		– Sell
-725,106
Closed -$7.98M – 87
2024
Q3 		$7.98M Sell
725,106
-250,500
-26% -$2.79M 1.09% 28
2024
Q2 		$8.88M Buy
975,606
+130,000
+15% +$1.27M 1.02% 29
2024
Q1 		$11.9M Sell
845,606
-620,859
-42% -$7.73M 1.47% 21
2023
Q4 		$11.3M Buy
1,466,465
+466,165
+47% +$2.58M 2.06% 17
2023
Q3 		$7.46M Buy
1,000,300
+349,425
+54% +$2.98M 2.1% 14
2023
Q2 		$5.42M Buy
650,875
+121,506
+23% +$1.4M 1.89% 18
2023
Q1 		$7.04M Buy
529,369
+56,887
+12% +$769K 2.32% 15
2022
Q4 		$7.04M Buy
472,482
+72,439
+18% +$747K 2.76% 13
2022
Q3 		$3.62M Buy
+400,043
New +$2.68M 1.01% 30

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Affinity Asset Advisors's ATXS Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 300,000 shares — an estimated $2.18M sold.

Affinity Asset Advisors first reported a position in ATXS in Q3 2022 and held it in 11 quarters. The position peaked at $11.9M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 300,000 Astria Therapeutics shares in Q4 2025, an estimated $2.18M.
  • Affinity Asset Advisors first reported a position in Astria Therapeutics in Q3 2022 and held it in 11 quarters.
  • Affinity Asset Advisors's Astria Therapeutics position peaked at $11.9M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.